Agenus | AGEN - Ebitda


Agenus reported $-10.11M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Agenus USD -10.11M 19.02M Mar/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Celldex Therapeutics USD -83.58M 2.76M Mar/2026
CSL USD 3.13B 1.17B Dec/2025
Eli Lilly USD 12.14B 4.26B Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Glaxosmithkline GBP 2.77B 1.98B Mar/2026
Incyte USD 367.97M 46.53M Mar/2026
Intrexon USD -24.7M 2.92M Jun/2024
J&J USD 7.19B 2.32B Dec/2025
Jiangsu Hengrui CNY 2.3B 678.46M Dec/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
MacroGenics USD -30.2M 52.15M Mar/2026
Merck EUR 1.53B 87M Mar/2026
Merck USD 6.3B 2.09B Dec/2025
Northwest Biotherapeutics USD -13.41M 232K Sep/2023
Novartis USD 5.3B 530M Mar/2026
Novavax USD 19.36M 190.79M Dec/2025
Pfizer USD 5.99B 5.23B Mar/2026
Regeneron Pharmaceuticals USD 1.2B 718.4M Dec/2025
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Veracyte USD 42.8M 488K Mar/2026